Clinical Trial Update: Tolvaptan-Octreotide LAR Combination in ADPKD [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a Tolvaptan-Octreotide LAR combination in autosomal dominant polycystic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Octreotide LAR (octreotide long-acting release)
• tolvaptan (tolvaptan)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: COMPLETED